QUANAO

Quanao Biopharma is a clinical-stage biotechnology company based in Suzhou, China, specializing in the development of innovative therapies for central nervous system (CNS) disorders. The company leverages a proprietary platform designed to optimize the blood-brain barrier (BBB) permeability of small molecule candidates, addressing a major hurdle in neuropharmacology. Their pipeline primarily targets neurodegenerative conditions such as Alzheimer's disease, Parkinson's disease, and Amyotrophic Lateral Sclerosis (ALS). By focusing on novel mechanisms of action related to neuroinflammation and protein homeostasis, Quanao aims to provide disease-modifying treatments for patients with high unmet medical needs. The company is backed by prominent venture capital firms and led by a team with extensive experience in neuroscience R&D.